Phase 3 Clinical Trials With Primary Completion Dates in April 2017

This is a list of Phase 3 trials with primary completion dates in April 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ARGSArgos Therapeutics, Inc.2017-04-01Phase 3NCT01582672Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
BIVVBioverativ Inc.2017-04-01Phase 3NCT02502149Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
CBPOChina Biologic Products, Inc.2017-04-01Phase 3NCT01979900Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
CEMPCempra, Inc.2017-04-01Phase 3NCT02210325Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea
CPHIChina Pharma Holdings, Inc.2017-04-01Phase 3NCT01979900Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis
NOVNNovan, Inc.2017-04-01Phase 3NCT02672332P3 Study in Acne Comparing Once Daily SB204 and Vehicle
NOVNNovan, Inc.2017-04-01Phase 3NCT02667444P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne
VRXValeant Pharmaceuticals International, Inc.2017-04-01Phase 3NCT02786901LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery